Patents by Inventor Ge Wu
Ge Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20170349643Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: June 12, 2017Publication date: December 7, 2017Applicant: Five Prime Therapeutics, Inc.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin G.P. Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20170194030Abstract: One variation of a method for serving interactive content to a user includes, at a visual element inserted into a document accessed by a computing device: loading a first frame from a digital video; in response to a scroll-down event that moves the visual element upward from a bottom of a window rendered on the computing device toward a top of the window, seeking from the first frame through a subset of frames in the digital video in a first direction at a rate corresponding to a scroll rate of the scroll-down event, the subset of frames spanning a duration of the digital video corresponding to a length of the scroll-down event; and, in response to termination of the scroll-down event with the visual element remaining in view within the window, playing the digital video forward from a last frame in the subset of frames in the digital video.Type: ApplicationFiled: March 22, 2017Publication date: July 6, 2017Inventors: Connor Francis Doherty, David Michael Goligorsky, Shawn Sprockett, Eric (Ge) Wu, Yiming Bao, Firecrow Silvernight
-
Publication number: 20170023798Abstract: A method for determining personalized near addition value for non-presbyopes, including measuring fusional amplitudes and phoria with at least one addition value, on both eyes of a person at a working distance; finding a mathematical function that predicts the change of a pair of fusional amplitudes and phoria as a function of addition value based on the addition value and the measured fusional amplitudes and phoria; and determining the near addition value according to a suitable relationship between the pair of fusional amplitudes and phoria on the mathematical function.Type: ApplicationFiled: March 7, 2014Publication date: January 26, 2017Applicant: ESSILOR INTERNATIONAL (COMPAGNIE GENERALE D'OPTIQUE)Inventors: XinPing YU, Jinhua BAO, Björn DROBE, Wehui LV, Hao CHEN, Jinling XU, Ge WU
-
Publication number: 20170024098Abstract: One variation of a method for serving interactive content to a user includes, at a visual element inserted into a document accessed by a computing device: loading a first frame from a digital video; in response to a scroll-down event that moves the visual element upward from a bottom of a window rendered on the computing device toward a top of the window, seeking from the first frame through a subset of frames in the digital video in a first direction at a rate corresponding to a scroll rate of the scroll-down event, the subset of frames spanning a duration of the digital video corresponding to a length of the scroll-down event; and, in response to termination of the scroll-down event with the visual element remaining in view within the window, playing the digital video forward from a last frame in the subset of frames in the digital video.Type: ApplicationFiled: July 22, 2016Publication date: January 26, 2017Inventors: Connor Francis Doherty, David Michael Goligorsky, Shawn Sprockett, Eric (Ge) Wu, Yiming Bao, Firecrow Silvernight
-
Publication number: 20160096876Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: October 7, 2015Publication date: April 7, 2016Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Patent number: 9192683Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: GrantFiled: October 8, 2013Date of Patent: November 24, 2015Assignee: FIVE PRIME THERAPEUTICS, INC.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Patent number: 9173957Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: GrantFiled: May 29, 2013Date of Patent: November 3, 2015Assignee: Five Prime Therapeutics, Inc.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20140170145Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: October 8, 2013Publication date: June 19, 2014Applicant: FIVE PRIME THERAPEUTICS, INC.Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20140140995Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: October 8, 2013Publication date: May 22, 2014Applicant: Five Prime Therapeutics, Inc.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen K. Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20130324701Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: May 29, 2013Publication date: December 5, 2013Applicant: FIVE PRIME THERAPEUTICS, INC.Inventors: Lewis T. WILLIAMS, Elizabeth BOSCH, Stephen K. DOBERSTEIN, Kevin HESTIR, Diane HOLLENBAUGH, Ernestine LEE, Minmin QIN QIN, Ali SADRA, Justin WONG, Ge WU, Hongbing ZHANG ZHANG
-
Patent number: 8580936Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: GrantFiled: September 7, 2011Date of Patent: November 12, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Patent number: 8575312Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: GrantFiled: April 13, 2012Date of Patent: November 5, 2013Assignee: Five Prime Therapeutics, Inc.Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20130065276Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: September 7, 2011Publication date: March 14, 2013Inventors: Lewis T. WILLIAMS, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20120301921Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: April 3, 2012Publication date: November 29, 2012Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20120258071Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: April 13, 2012Publication date: October 11, 2012Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Patent number: 8178109Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: GrantFiled: February 12, 2009Date of Patent: May 15, 2012Assignee: Five Prime Therapeutics, Inc.Inventors: Dirk Behrens, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams
-
Publication number: 20110319324Abstract: The present invention relates to therapeutic uses of ErbB ligands, including betacellulin. The therapeutic uses include methods of using ErbB ligand family compounds alone, or in conjunction with other agents, for reducing blood glucose levels, treating Type I and Type II diabetes, obesity, muscle wasting diseases, and cardiotoxicity.Type: ApplicationFiled: November 29, 2010Publication date: December 29, 2011Inventors: Junyu Lin, Srinivas Kothakota, Ge Wu, Stephen Doberstein, Thomas Brennan, Lorianne Masuoka, Minmin Qin, Shannon Marshall, Yan Wang, Diane Hollenbaugh, Lewis T. Williams
-
Publication number: 20110281302Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: ApplicationFiled: June 10, 2011Publication date: November 17, 2011Inventors: Lewis T. WILLIAMS, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Patent number: 7982014Abstract: The invention provides FGFR fusion proteins, methods of making them, and methods of using them to treat proliferative disorders, including cancers and disorders of angiogenesis. The FGFR fusion molecules can be made in CHO cells and may comprise deletion mutations in the extracellular domains of the FGFRs which improve their stability. These fusion proteins inhibit the growth and viability of cancer cells in vitro and in vivo. The combination of the relatively high affinity of these receptors for their ligand FGFs and the demonstrated ability of these decoy receptors to inhibit tumor growth is an indication of the clinical value of the compositions and methods provided herein.Type: GrantFiled: January 5, 2010Date of Patent: July 19, 2011Assignee: Five Prime Therapeutics, Inc.Inventors: Lewis T. Williams, Elizabeth Bosch, Stephen Doberstein, Kevin Hestir, Diane Hollenbaugh, Ernestine Lee, Minmin Qin, Ali Sadra, Justin Wong, Ge Wu, Hongbing Zhang
-
Publication number: 20110003384Abstract: Disclosed is a newly identified secreted molecule, identified herein as “monocyte, granulocyte, and dendritic cell colony stimulating factor” (MGD-CSF), the polypeptide sequence, and polynucleotides encoding the polypeptide sequence. Also provided is a procedure for producing the polypeptide by recombinant techniques employing, for example, vectors and host cells. Additionally, procedures are described to modify the disclosed novel molecules of the invention to prepare fusion molecules. Also disclosed are methods for using the polypeptides and active fragments thereof for treatment of a variety of diseases, including, for example, cancer, autoimmune and inflammatory diseases, infectious diseases, and recurrent pregnancy loss.Type: ApplicationFiled: February 12, 2009Publication date: January 6, 2011Inventors: Dirk BEHRENS, Elizabeth Bosch, Stephen K. Doberstein, Robert Forgan Halenbeck, Kevin Hestir, Min Mei Huang, Ernestine Lee, Haishan Lin, Thomas Linnemann, Shannon Marshall, Justin G. P. Wong, Ge Wu, Aileen Zhou, Cindy Leo, Lewis T. Williams